ATG-027

N/A

Report date: 2024/07/02 17:46:23

First In Class

Base Information

Drug NameATG-027

Drug Alias NameATG-027

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCD276 antigen inhibitorsAnti-Programmed death-ligand 1Antibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4]

TargetsCD276 antigenProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAntengene Corporation Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAntengene Corporation Co Ltd

Inactive CompaniesAntengene Corp Ltd

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A